deltatrials
Terminated OBSERVATIONAL NCT01039311

Optical Coherence Tomography: An Adjunct to Flexible Bronchoscopy in the Diagnosis of Lung Cancer (OCT)

Sponsor: University of Oklahoma

Conditions Lung Cancer
Updated 8 times since 2017 Last updated: Jan 31, 2013 Started: Feb 28, 2009 Primary completion: Sep 30, 2012 Completion: Sep 30, 2012
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Unable to enroll subjects

This observational or N/A phase trial investigates Lung Cancer and is currently terminated or withdrawn. University of Oklahoma leads this study, which shows 8 recorded versions since 2009 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Study Description(click to expand)

OCT could become a powerful tool in diagnostic pulmonary medicine, not only in the early recognition of lung cancer, but also in the evaluation and monitoring of microstructures in the lower respiratory tract that are affected by other inflammatory or invasive disease processes. Initially, OCT could be used to guide the location of biopsies which would likely provide increased specificity to traditional bronchoscopy. However, if the sensitivity and specificity of OCT images are comparable to histologic specimens, this technology may in the future provide a non-invasive "optical biopsy", which could potentially obviate the need for conventional biopsies in patients with high risks for complications, such as bleeding.

OCT could become a powerful tool in diagnostic pulmonary medicine, not only in the early recognition of lung cancer, but also in the evaluation and monitoring of microstructures in the lower respiratory tract that are affected by other inflammatory or invasive disease processes. Initially, OCT could be used to guide the location of biopsies which would likely provide increased specificity to traditional bronchoscopy. However, if the sensitivity and specificity of OCT images are comparable to histologic specimens, this technology may in the future provide a non-invasive "optical biopsy", which could potentially obviate the need for conventional biopsies in patients with high risks for complications, such as bleeding.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotTerminated~Feb 2017 – ~Apr 2018 · 14 months · monthly snapshotTerminated~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshotTerminated~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotTerminated~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 19 months · monthly snapshotTerminated~Jan 2026 – present · 3 months · monthly snapshotTerminated

Change History

8 versions recorded
  1. Jan 2026 — Present [monthly]

    Terminated

  2. Sep 2024 — Present [monthly]

    Terminated

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated

  4. Jan 2021 — Jul 2024 [monthly]

    Terminated

  5. Jun 2018 — Jan 2021 [monthly]

    Terminated

Show 3 earlier versions
  1. Apr 2018 — Jun 2018 [monthly]

    Terminated

    Phase: NANone

  2. Feb 2017 — Apr 2018 [monthly]

    Terminated NA

  3. Jan 2017 — Feb 2017 [monthly]

    Terminated NA

    First recorded

Feb 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • University of Oklahoma
Data source: University of Oklahoma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations